<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39319296</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2296-2565</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in public health</Title><ISOAbbreviation>Front Public Health</ISOAbbreviation></Journal><ArticleTitle>Personal characteristics and transmission dynamics associated with SARS-CoV-2 semi-quantitative PCR test results: an observational study from Belgium, 2021-2022.</ArticleTitle><Pagination><StartPage>1429021</StartPage><MedlinePgn>1429021</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1429021</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpubh.2024.1429021</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Following harmonization efforts by the Belgian National Reference Center for SARS-CoV-2, semi-quantitative PCR test (SQ-PCR) results, used as a proxy for viral load, were routinely collected after performing RT-qPCR tests.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We investigated both the personal characteristics associated with SQ-PCR results and the transmission dynamics involving these results. We used person-level laboratory test data and contact tracing data collected in Belgium from March 2021 to February 2022. Personal characteristics (age, sex, vaccination, and laboratory-confirmed prior infection) and disease stage by date of symptom onset were analyzed in relation to SQ-PCR results using logistic regression. Vaccine effectiveness (VE) against a high viral load (≥10<sup>7</sup> copies/mL) was estimated from the adjusted probabilities. Contact tracing involves the mandatory testing of high-risk exposure contacts (HREC) after contact with an index case. Odds ratios for test positivity and high viral load in HREC were calculated based on the SQ-PCR result of the index case using logistic regression models adjusted for age, sex, immunity status (vaccination, laboratory-confirmed prior infection), variant (Alpha, Delta, Omicron), calendar time, and contact tracing covariates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We included 909,157 SQ-PCR results of COVID-19 cases, 379,640 PCR results from index cases, and 72,052 SQ-PCR results of HREC. High viral load was observed more frequently among recent cases, symptomatic cases, cases over 25 years of age, and those not recently vaccinated (&gt;90 days). The vaccine effectiveness (VE) of the primary schedule in the first 30 days after vaccination was estimated at 47.3% (95%CI 40.8-53.2) during the Delta variant period. A high viral load in index cases was associated with an increased test positivity in HREC (OR 2.7, 95%CI 2.62-2.79) and, among those testing positive, an increased likelihood of a high viral load (OR 2.84, 95%CI 2.53-3.19).</AbstractText><CopyrightInformation>Copyright © 2024 Braeye, Proesmans, Van Cauteren, Brondeel, Hens, Vermeiren, Hammami, Rosas, Taame, André and Cuypers.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Braeye</LastName><ForeName>Toon</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Epidemiology of Infectious Diseases, Sciensano, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>I-BioStat, Data Science Institute, Hasselt University, Hasselt, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proesmans</LastName><ForeName>Kristiaan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, Department of Bio-analysis, Ghent University, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Cauteren</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Epidemiology of Infectious Diseases, Sciensano, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brondeel</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Epidemiology of Infectious Diseases, Sciensano, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hens</LastName><ForeName>Niel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>I-BioStat, Data Science Institute, Hasselt University, Hasselt, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Health Economic Research and Modelling Infectious Diseases, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vermeiren</LastName><ForeName>Elias</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Epidemiology of Infectious Diseases, Sciensano, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammami</LastName><ForeName>Naïma</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Care, Infection Prevention and Control, Flemish Community, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosas</LastName><ForeName>Angel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Direction Surveillance des Maladies Infectieuses, Agence out une Vie de Qualité (AVIQ), Charleroi, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taame</LastName><ForeName>Adrae</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cellule de médecine préventive- Direction santé et aide aux personnes - Vivalis/Cocom, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>André</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, National Reference Centre for Respiratory Pathogens, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical Microbiology, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuypers</LastName><ForeName>Lize</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, National Reference Centre for Respiratory Pathogens, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical Microbiology, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Public Health</MedlineTA><NlmUniqueID>101616579</NlmUniqueID><ISSNLinking>2296-2565</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001530" MajorTopicYN="N" Type="Geographic">Belgium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="Y">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016358" MajorTopicYN="Y">Contact Tracing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087123" MajorTopicYN="N">COVID-19 Nucleic Acid Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="N">Vaccine Efficacy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">contact tracing</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">transmission</Keyword><Keyword MajorTopicYN="N">vaccine effectiveness</Keyword><Keyword MajorTopicYN="N">viral load</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>4</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39319296</ArticleId><ArticleId IdType="pmc">PMC11420023</ArticleId><ArticleId IdType="doi">10.3389/fpubh.2024.1429021</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bustos Sierra N, Bossuyt N, Braeye T, Leroy M, Moyersoen I, Peeters I, et al. . All-cause mortality supports the COVID-19 mortality in Belgium and comparison with major fatal events of the last century. Arch Public Health. (2020) 78:117. doi: 10.1186/s13690-020-00496-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13690-020-00496-x</ArticleId><ArticleId IdType="pmc">PMC7662738</ArticleId><ArticleId IdType="pubmed">33292536</ArticleId></ArticleIdList></Reference><Reference><Citation>Meurisse M, Lajot A, Dupont Y, Lesenfants M, Klamer S, Rebolledo J, et al. . One year of laboratory-based COVID-19 surveillance system in Belgium: main indicators and performance of the laboratories (march 2020-21). Arch Public Health Arch Belg Sante Publique. (2021) 79:188. doi: 10.1186/s13690-021-00704-2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13690-021-00704-2</ArticleId><ArticleId IdType="pmc">PMC8548266</ArticleId><ArticleId IdType="pubmed">34706768</ArticleId></ArticleIdList></Reference><Reference><Citation>Goethem NV, Vilain A, Wyndham-Thomas C, Deblonde J, Bossuyt N, Lernout T, et al. . Rapid establishment of a national surveillance of COVID-19 hospitalizations in Belgium. Arch Public Health Arch Belg Sante Publique. (2020) 78:121. doi: 10.1186/s13690-020-00505-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13690-020-00505-z</ArticleId><ArticleId IdType="pmc">PMC7673251</ArticleId><ArticleId IdType="pubmed">33292566</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen R, Cuypers L, Laenen L, Keyaerts E, Beuselinck K, Janssenswillen S, et al. . Nationwide quality assurance of high-throughput diagnostic molecular testing during the SARS-CoV-2 pandemic: role of the Belgian National Reference Centre. Virol J. (2024) 21:40. doi: 10.1186/s12985-024-02308-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-024-02308-y</ArticleId><ArticleId IdType="pmc">PMC10858549</ArticleId><ArticleId IdType="pubmed">38341597</ArticleId></ArticleIdList></Reference><Reference><Citation>Proesmans K, Hancart S, Braeye T, Klamer S, Robesyn E, Djiena A, et al. . COVID-19 contact tracing in Belgium: main indicators and performance, January – September 2021. Arch Public Health. (2022) 80:118. doi: 10.1186/s13690-022-00875-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13690-022-00875-6</ArticleId><ArticleId IdType="pmc">PMC9005619</ArticleId><ArticleId IdType="pubmed">35418097</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremer C, Willem L, Boone J, de Oñate WA, Hammami N, Faes C, et al. . Key performance indicators of COVID-19 contact tracing in Belgium from September 2020 to December 2021. PLoS One. (2023) 18:e0292346. doi: 10.1371/journal.pone.0292346, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0292346</ArticleId><ArticleId IdType="pmc">PMC10588862</ArticleId><ArticleId IdType="pubmed">37862313</ArticleId></ArticleIdList></Reference><Reference><Citation>Algemeen . (2022). Coronavirus COVID-19. Available online at: https://covid-19.sciensano.be/nl/procedures/algemeen (Accessed 6 July, 2023).</Citation></Reference><Reference><Citation>Sciensano . (2022) Weekly COVID-19 bulletin. Available online at: https://covid-19.sciensano.be/sites/default/files/Covid19/COVID-19_Weekly%20report_20220107%20-%20NL.pdf (Accessed 22 October, 2023).</Citation></Reference><Reference><Citation>Viloria Winnett A, Akana R, Shelby N, Davich H, Caldera S, Yamada T, et al. . Extreme differences in SARS-CoV-2 viral loads among respiratory specimen types during presumed pre-infectious and infectious periods. PNAS Nexus. (2023). doi: 10.1093/pnasnexus/pgad033</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pnasnexus/pgad033</ArticleId><ArticleId IdType="pmc">PMC10013338</ArticleId><ArticleId IdType="pubmed">36926220</ArticleId></ArticleIdList></Reference><Reference><Citation>Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding kinetics. Nat Rev Microbiol. (2023) 21:147–61. doi: 10.1038/s41579-022-00822-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00822-w</ArticleId><ArticleId IdType="pmc">PMC9716513</ArticleId><ArticleId IdType="pubmed">36460930</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, et al. . SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. (2020) 11:5493. doi: 10.1038/s41467-020-19057-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19057-5</ArticleId><ArticleId IdType="pmc">PMC7603483</ArticleId><ArticleId IdType="pubmed">33127906</ArticleId></ArticleIdList></Reference><Reference><Citation>Marc A, Kerioui M, Blanquart F, Bertrand J, Mitjà O, Corbacho-Monné M, et al. . Quantifying the relationship between SARS-CoV-2 viral load and infectiousness. eLife. (2021) 10:e69302. doi: 10.7554/eLife.69302</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.69302</ArticleId><ArticleId IdType="pmc">PMC8476126</ArticleId><ArticleId IdType="pubmed">34569939</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavina K, Franco LC, Robinson CM, Hymas W, Lei GS, Sinclair W, et al. . Standardization of SARS-CoV-2 cycle threshold values: multisite investigation evaluating viral quantitation across multiple commercial COVID-19 detection platforms. Microbiol Spectr. (2023) 11:e04470–22. doi: 10.1128/spectrum.04470-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.04470-22</ArticleId><ArticleId IdType="pmc">PMC9927101</ArticleId><ArticleId IdType="pubmed">36651781</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuypers L, Bode J, Beuselinck K, Laenen L, Dewaele K, Janssen R, et al. . Nationwide harmonization effort for semi-quantitative reporting of SARS-CoV-2 PCR test results in Belgium. Viruses. (2022) 14:1294. doi: 10.3390/v14061294, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14061294</ArticleId><ArticleId IdType="pmc">PMC9230955</ArticleId><ArticleId IdType="pubmed">35746765</ArticleId></ArticleIdList></Reference><Reference><Citation>To KK-W, Tsang OTY, Leung WS, Tam AR, Wu TC, Lung DC, et al. . Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. (2020) 20:565–74. doi: 10.1016/S1473-3099(20)30196-1, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30196-1</ArticleId><ArticleId IdType="pmc">PMC7158907</ArticleId><ArticleId IdType="pubmed">32213337</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. . Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. (2020) 26:672–5. doi: 10.1038/s41591-020-0869-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0869-5</ArticleId><ArticleId IdType="pubmed">32296168</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuypers L, Dellicour S, Hong SL, Potter BI, Verhasselt B, Vereecke N, et al. . Two years of genomic surveillance in Belgium during the SARS-CoV-2 pandemic to attain country-wide coverage and monitor the introduction and spread of emerging variants. Viruses. (2022) 14:2301. doi: 10.3390/v14102301, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14102301</ArticleId><ArticleId IdType="pmc">PMC9612291</ArticleId><ArticleId IdType="pubmed">36298856</ArticleId></ArticleIdList></Reference><Reference><Citation>Looker Studio . (n.d.) Belgium COVID-19 Dashboard – Sciensano. Available online at: http://lookerstudio.google.com/reporting/c14a5cfc-cab7-4812-848c-0369173148ab (Accessed 11 October, 2023).</Citation></Reference><Reference><Citation>Cori A, Ferguson NM, Fraser C, Cauchemez S. A new framework and software to estimate time-varying reproduction numbers during epidemics. Am J Epidemiol. (2013) 178:1505–12. doi: 10.1093/aje/kwt133</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwt133</ArticleId><ArticleId IdType="pmc">PMC3816335</ArticleId><ArticleId IdType="pubmed">24043437</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalgaard Peter. (2022). [Rd] R 4.2.1 is released. Available online at: https://stat.ethz.ch/pipermail/r-announce/2022/000685.html (Accessed 19 January, 2023).</Citation></Reference><Reference><Citation>Marking U, Havervall S, Norin NG, Bladh O, Christ W, Gordon M, et al. . Correlates of protection, viral load trajectories and symptoms in BA.1, BA.1.1 and BA.2 breakthrough infections in triple vaccinated healthcare workers [internet]. medRxiv. (2022). doi: 10.1101/2022.04.02.22273333v2</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.04.02.22273333v2</ArticleId><ArticleId IdType="pmc">PMC10031702</ArticleId><ArticleId IdType="pubmed">36949041</ArticleId></ArticleIdList></Reference><Reference><Citation>Stankiewicz Karita HC, Dong TQ, Johnston C, Neuzil KM, Paasche-Orlow MK, Kissinger PJ, et al. . Trajectory of viral RNA load among persons with incident SARS-CoV-2 G614 infection (Wuhan strain) in association with COVID-19 symptom onset and severity. JAMA Netw Open. (2022) 5:e2142796. doi: 10.1001/jamanetworkopen.2021.42796, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.42796</ArticleId><ArticleId IdType="pmc">PMC8749477</ArticleId><ArticleId IdType="pubmed">35006245</ArticleId></ArticleIdList></Reference><Reference><Citation>Hay JA, Kissler SM, Fauver JR, Mack C, Tai CG, Samant RM, et al. . Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: a retrospective cohort study. eLife. (2022) 11:e81849. doi: 10.7554/eLife.81849</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.81849</ArticleId><ArticleId IdType="pmc">PMC9711520</ArticleId><ArticleId IdType="pubmed">36383192</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke R, Martinez PP, Smith RL, Gibson LL, Mirza A, Conte M, et al. . Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness. Nat Microbiol. (2022) 7:640–52. doi: 10.1038/s41564-022-01105-z, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01105-z</ArticleId><ArticleId IdType="pmc">PMC9084242</ArticleId><ArticleId IdType="pubmed">35484231</ArticleId></ArticleIdList></Reference><Reference><Citation>Frediani JK, Parsons R, McLendon KB, Westbrook AL, Lam W, Martin G, et al. . The new Normal: delayed peak severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral loads relative to symptom onset and implications for coronavirus disease 2019 (COVID-19) testing programs. Clin Infect Dis. (2023) ciad582. doi: 10.1093/cid/ciad582</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad582</ArticleId><ArticleId IdType="pmc">PMC10874267</ArticleId><ArticleId IdType="pubmed">37768707</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindeboom RGH, Worlock KB, Dratva LM, Yoshida M, Scobie D, Wagstaffe HR, et al. . Human SARS-CoV-2 challenge uncovers local and systemic response dynamics. Nature. (2024) 631:189–98. doi: 10.1038/s41586-024-07575-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-024-07575-x</ArticleId><ArticleId IdType="pmc">PMC11222146</ArticleId><ArticleId IdType="pubmed">38898278</ArticleId></ArticleIdList></Reference><Reference><Citation>Hay JA, Kennedy-Shaffer L, Kanjilal S, Lennon NJ, Gabriel SB, Lipsitch M, et al. . Estimating epidemiologic dynamics from cross-sectional viral load distributions. Science. (2021) 373:eabh0635. doi: 10.1126/science.abh0635</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abh0635</ArticleId><ArticleId IdType="pmc">PMC8527857</ArticleId><ArticleId IdType="pubmed">34083451</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Yang B, Cobey S, Lau EHY, Adam DC, Wong JY, et al. . Incorporating temporal distribution of population-level viral load enables real-time estimation of COVID-19 transmission. Nat Commun. (2022) 13:1155. doi: 10.1038/s41467-022-28812-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28812-9</ArticleId><ArticleId IdType="pmc">PMC8894407</ArticleId><ArticleId IdType="pubmed">35241662</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala E, Shah IS, Manissero D, Juanola-Falgarona M, Quirke AM, Rao SN. Systematic review on the correlation between SARS-CoV-2 real-time PCR cycle threshold values and epidemiological trends. Infect Dis Ther. (2023) 12:749–75. doi: 10.1007/s40121-023-00772-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-023-00772-7</ArticleId><ArticleId IdType="pmc">PMC9945817</ArticleId><ArticleId IdType="pubmed">36811776</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin N, Dellicour S, Daubie V, Franco N, Wautier M, Faes C, et al. . Leveraging of SARS-CoV-2 PCR cycle thresholds values to forecast COVID-19 trends. Front Med. (2021) 8:743988. doi: 10.3389/fmed.2021.743988</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.743988</ArticleId><ArticleId IdType="pmc">PMC8591051</ArticleId><ArticleId IdType="pubmed">34790677</ArticleId></ArticleIdList></Reference><Reference><Citation>Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. (2021) 2:e13–22. doi: 10.1016/S2666-5247(20)30172-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(20)30172-5</ArticleId><ArticleId IdType="pmc">PMC7837230</ArticleId><ArticleId IdType="pubmed">33521734</ArticleId></ArticleIdList></Reference><Reference><Citation>Siedner MJ, Boucau J, Gilbert RF, Uddin R, Luu J, Haneuse S, et al. . Duration of viral shedding and culture positivity with postvaccination SARS-CoV-2 delta variant infections. JCI Insight. 7:e155483</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8855795</ArticleId><ArticleId IdType="pubmed">34871181</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadras O, Afsahi AM, Pashaei Z, Mojdeganlou H, Karimi A, Habibi P, et al. . The relationship between COVID-19 viral load and disease severity: a systematic review. Immun Inflamm Dis. (2022) 10:e580. doi: 10.1002/iid3.580</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.580</ArticleId><ArticleId IdType="pmc">PMC8926507</ArticleId><ArticleId IdType="pubmed">34904379</ArticleId></ArticleIdList></Reference><Reference><Citation>Singanayagam A, Hakki S, Dunning J, Madon KJ, Crone MA, Koycheva A, et al. . Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis. (2021) 22:183–95. doi: 10.1016/S1473-3099(21)00648-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00648-4</ArticleId><ArticleId IdType="pmc">PMC8554486</ArticleId><ArticleId IdType="pubmed">34756186</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Mi H, Li N, Shi Q, Sun W, He T, et al. . Association between the overall burden of comorbidity and Ct values among the older patients with omicron infection: mediated by inflammation. Front Immunol. (2023) 14:14. doi: 10.3389/fimmu.2023.1145044, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1145044</ArticleId><ArticleId IdType="pmc">PMC10043200</ArticleId><ArticleId IdType="pubmed">36999038</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontana LM, Villamagna AH, Sikka MK, McGregor JC. Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): review of current literature. Infect Control Hosp Epidemiol. (2021) 42:659–68. doi: 10.1017/ice.2020.1273</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ice.2020.1273</ArticleId><ArticleId IdType="pmc">PMC7691645</ArticleId><ArticleId IdType="pubmed">33077007</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine-Tiefenbrun M, Yelin I, Alapi H, Herzel E, Kuint J, Chodick G, et al. . Waning of SARS-CoV-2 booster viral-load reduction effectiveness. Nat Commun. (2022) 13:1237. doi: 10.1038/s41467-022-28936-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28936-y</ArticleId><ArticleId IdType="pmc">PMC8897467</ArticleId><ArticleId IdType="pubmed">35246560</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodbridge Y, Amit S, Huppert A, Kopelman NM. Viral load dynamics of SARS-CoV-2 Delta and omicron variants following multiple vaccine doses and previous infection. Nat Commun. (2022) 13:6706. doi: 10.1038/s41467-022-33096-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33096-0</ArticleId><ArticleId IdType="pmc">PMC9640564</ArticleId><ArticleId IdType="pubmed">36344489</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman S, Rahman MM, Miah M, Begum MN, Sarmin M, Mahfuz M, et al. . COVID-19 reinfections among naturally infected and vaccinated individuals. Sci Rep. (2022) 12:1438. doi: 10.1038/s41598-022-05325-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-05325-5</ArticleId><ArticleId IdType="pmc">PMC8792012</ArticleId><ArticleId IdType="pubmed">35082344</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee LYW, Rozmanowski S, Pang M, Charlett A, Anderson C, Hughes GJ, et al. . Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity by viral load, S gene variants and demographic factors, and the utility of lateral flow devices to prevent transmission. Clin Infect Dis Off Publ Infect Dis Soc Am. (2022) 74:407–15. doi: 10.1093/cid/ciab421, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab421</ArticleId><ArticleId IdType="pmc">PMC8136027</ArticleId><ArticleId IdType="pubmed">33972994</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks M, Millat-Martinez P, Ouchi D, Roberts CH, Alemany A, Corbacho-Monné M, et al. . Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. Lancet Infect Dis. (2021) 21:629–36. doi: 10.1016/S1473-3099(20)30985-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30985-3</ArticleId><ArticleId IdType="pmc">PMC7906723</ArticleId><ArticleId IdType="pubmed">33545090</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyngse FP, Mølbak K, Skov RL, Christiansen LE, Mortensen LH, Albertsen M, et al. . Increased transmissibility of SARS-CoV-2 lineage B.1.1.7 by age and viral load. Nat Commun. (2021) 12:7251. doi: 10.1038/s41467-021-27202-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27202-x</ArticleId><ArticleId IdType="pmc">PMC8669007</ArticleId><ArticleId IdType="pubmed">34903718</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhavnani D, James ER, Johnson KE, Beaudenon-Huibregtse S, Chang P, Rathouz PJ, et al. . SARS-CoV-2 viral load is associated with risk of transmission to household and community contacts. BMC Infect Dis. (2022) 22:672. doi: 10.1186/s12879-022-07663-1, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07663-1</ArticleId><ArticleId IdType="pmc">PMC9354300</ArticleId><ArticleId IdType="pubmed">35931971</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe T, Bartrand TA, Weir MH, Omura T, Haas CN. Development of a dose-response model for SARS coronavirus. Risk Anal. (2010) 30:1129–38. doi: 10.1111/j.1539-6924.2010.01427.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1539-6924.2010.01427.x</ArticleId><ArticleId IdType="pmc">PMC7169223</ArticleId><ArticleId IdType="pubmed">20497390</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal A, Reeves DB, Cardozo-Ojeda EF, Schiffer JT, Mayer BT. Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events. eLife. (2021) 10:e63537. doi: 10.7554/eLife.63537</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.63537</ArticleId><ArticleId IdType="pmc">PMC7929560</ArticleId><ArticleId IdType="pubmed">33620317</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerami C, Popkin-Hall ZR, Rapp T, Tompkins K, Zhang H, Muller MS, et al. . Household transmission of severe acute respiratory syndrome coronavirus 2 in the United States: living density, viral load, and disproportionate impact on communities of color. Clin Infect Dis. (2022) 74:1776–85. doi: 10.1093/cid/ciab701</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab701</ArticleId><ArticleId IdType="pmc">PMC8436395</ArticleId><ArticleId IdType="pubmed">34383889</ArticleId></ArticleIdList></Reference><Reference><Citation>Methi F, Madslien EH. Lower transmissibility of SARS-CoV-2 among asymptomatic cases: evidence from contact tracing data in Oslo, Norway. BMC Med. (2022) 20:427. doi: 10.1186/s12916-022-02642-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02642-4</ArticleId><ArticleId IdType="pmc">PMC9641677</ArticleId><ArticleId IdType="pubmed">36348327</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuin M, Gentili V, Cervellati C, Rizzo R, Zuliani G. Viral load difference between symptomatic and asymptomatic COVID-19 patients: systematic review and Meta-analysis. Infect Dis Rep. (2021) 13:645–53. doi: 10.3390/idr13030061</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/idr13030061</ArticleId><ArticleId IdType="pmc">PMC8293148</ArticleId><ArticleId IdType="pubmed">34287354</ArticleId></ArticleIdList></Reference><Reference><Citation>Ra SH, Lim JS, Kim G-U, Kim MJ, Jung J, Kim S-H. Upper respiratory viral load in asymptomatic individuals and mildly symptomatic patients with SARS-CoV-2 infection. Thorax. (2021) 76:61–3. doi: 10.1136/thoraxjnl-2020-215042, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-215042</ArticleId><ArticleId IdType="pubmed">32963115</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae S, Kim JY, Lim SY, Park H, Cha HH, Kwon JS, et al. . Dynamics of viral shedding and symptoms in patients with asymptomatic or mild COVID-19. Viruses. (2021) 13:2133. doi: 10.3390/v13112133, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13112133</ArticleId><ArticleId IdType="pmc">PMC8625453</ArticleId><ArticleId IdType="pubmed">34834940</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher LH, Kee JJ, Liu A, Espinosa CM, Randhawa AK, Ludwig J, et al. . SARS-CoV-2 viral load in the nasopharynx at time of first infection among unvaccinated individuals: a secondary cross-protocol analysis of 4 randomized trials. JAMA Netw Open. (2024) 7:e2412835. doi: 10.1001/jamanetworkopen.2024.12835, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2024.12835</ArticleId><ArticleId IdType="pmc">PMC11117088</ArticleId><ArticleId IdType="pubmed">38780941</ArticleId></ArticleIdList></Reference><Reference><Citation>Braeye T. (2024). Performance of SARS-CoV-2 contact tracing in Belgium (2020–2022).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>